FDA Approves Cangrelor (Kengreal) for PCIFDA Approves Cangrelor (Kengreal) for PCI
The approval in the PCI setting is based on data from CHAMPION-PHOENIX, where cangrelor reduced the risk of thrombotic events compared with patients treated clopidogrel. FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 22, 2015 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Taking Certain Heartburn Meds Linked To Higher Risk Of Heart Attack
By Kathryn Doyle (Reuters Health) - People who take certain popular heartburn medications, like omeprazole (Prilosec), are at increased risk of heart attack, according to a data mining study by U.S. researchers. The drugs, called proton-pump inhibitors (PPIs), lower acidity in the stomach and prevent the burning sensation in the esophagus that indicates acid reflux. There have been questions about the safety of these drugs for people who have had a coronary event like a heart attack, said lead author Nigam H. Shah of Stanford University in California, but most research h...
Source: Science - The Huffington Post - June 10, 2015 Category: Science Source Type: news
Clopidogrel/Aspirin Combo Helps After Stroke, TIA
(MedPage Today) -- Decreases stroke risk without increasing chance of hemorrhage. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - May 27, 2015 Category: Pediatrics Source Type: news
ASK THE DOCTOR: Do I really need to keep taking my stroke tablets?
Graham had a transient ischaemic attack ten months ago and wonders whether he still needs to take clopidogrel. Dr Scurr advises. (Source: the Mail online | Health)
Source: the Mail online | Health - April 13, 2015 Category: Consumer Health News Source Type: news
Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY® (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease
Dateline City:
KENILWORTH, N.J.
These and other post-hoc subgroup analyses from TRA-2°P are being presented at the 2015 American College of Cardiology Scientific Sessions
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced
results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin
Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic
Events) trial of ZONTIVITY® (vora...
Source: Merck.com - Product News - March 5, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Scientists find a key protein that allows Plavix to conquer platelets
(University of North Carolina Health Care) UNC School of Medicine researchers found that the blood platelet protein Rasa3 is critical to the success of the common anti-platelet drug Plavix, which breaks up blood clots during heart attacks and other arterial diseases. The discovery details how Rasa3 is part of a cellular pathway crucial for platelet activity during clot formation. Understanding the protein's role could also prove vital in the development of new compounds aimed at altering platelet function. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 23, 2015 Category: Biology Source Type: news
Millions of adults skip medications due to their high cost
Medications can do wonderful things, from fighting infection to preventing stroke and warding off depression. But medications don’t work if they aren’t taken. Some people don’t take their medications as prescribed because they forget, or are bothered by side effects. A new report from the National Center for Health Statistics shines the light on another reason: some people can’t pay for their medications.
The survey, by NCHS researchers Robin A. Cohen and Maria A. Villarroel, found that about 8% of adult Americans don’t take their medicines as prescribed because they can’t afford them. I...
Source: New Harvard Health Information - January 30, 2015 Category: Consumer Health News Authors: Howard LeWine, M.D. Tags: Drugs and Supplements medication costs Source Type: news
Clopidogrel-PPI Interaction Questioned in Meta-analysisClopidogrel-PPI Interaction Questioned in Meta-analysis
Randomized trials say no such interaction exists but observational studies suggest otherwise, concludes a new analysis. But are the observational studies "hopelessly confounded," as an expert insists? Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 27, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Vorapaxar and Clopidogrel After Non-ST ACSVorapaxar and Clopidogrel After Non-ST ACS
What's the modification of vorapaxar's effect associated with clopidogrel use in patients with acute coronary syndromes? American Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2014 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
DAPT Study: Extended Treatment After Stenting Lowers Stent Thrombosis and Heart Attacks
"Longer is better." That's what Dr. Dean Kereiakis told Angioplasty.Org when characterizing the results of the long-awaited Dual Antiplatelet Therapy (DAPT) study, which were presented today at the annual American Heart Association Scientific Sessions in Chicago. Dr. Kereiakes is the co-principal investigator for this five year study of 10,000 patients, which adds to the knowledge base of whether long-term treatment with aspirin and a thienopyridine, such as Plavix, after stent implantation is beneficial to patients. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - November 16, 2014 Category: Cardiology Source Type: news
Long-term Antiplatelet Therapy: Safety Announcement - Preliminary Trial Data Shows Benefits But a Higher Risk of Non-Cardiovascular Death
FDA believes the benefits of clopidogrel (Plavix) and prasugrel (Effient) therapy continue to outweigh their potential risks when used for approved uses. (Source: FDA MedWatch)
Source: FDA MedWatch - November 16, 2014 Category: American Health Source Type: news
ISAR-TRIPLE: Six-Week vs Six-Month Clopidogrel in DES and AF ISAR-TRIPLE: Six-Week vs Six-Month Clopidogrel in DES and AF
Dr Sarafoff reviews his trial on clopidogrel duration in patients taking oral anticoagulation and aspirin. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 1, 2014 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Reassuring Data on Use of DAPT and AnticoagulationReassuring Data on Use of DAPT and Anticoagulation
For patients requiring triple therapy in the ISAR-TRIPLE study, the data suggest that stopping clopidogrel after six weeks won't reduce the bleeding risk, but it won't up the risk of ischemic events either. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 15, 2014 Category: Cardiology Tags: Cardiology News Source Type: news
Heart patients in England and Wales offered more treatment choice
Revised guidance from the National Institute for Health and Care Excellence, recommends once-daily, oral antiplatelet prasugrel (Efient®), in combination with aspirin, as a cost-effective option compared with generic clopidogrel, for a wider group of acute coronary syndrome patients having primary or delayed percutaneous coronary intervention. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 24, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Cardiovascular medicine acs acute coronary syndrome aspirin clopidogrel Efient® Latest News National Institute for Health and Care Excellence pci percutaneous coronary intervention prasugrel Source Type: news
CHMP Recommends Approval of Clopidogrel/ASA ComboCHMP Recommends Approval of Clopidogrel/ASA Combo
The drug would be available in two doses—clopidogrel 75 mg/aspirin 75 mg and clopidogrel 75 mg/aspirin 100 mg—for patients at risk for atherothrombotic events already taking both drugs. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
